Table of Contents Author Guidelines Submit a Manuscript

Cutaneous Side Effects of Targeted Therapy

Call for Papers

In recent years, there has been a rapid emergence of numerous targeted anticancer therapies. Targeted therapies, unlike standard chemotherapy agents which lead to systemic toxicities, are frequently associated with cutaneous adverse events that may be responsible for dose reduction or therapy discontinuation.

Given the rapid growth of targeted anticancer treatments, dermatologists will be essential in the recognition of these cutaneous complications, particularly since dermatologic toxicities are shown to positively correlate with response to therapy. Furthermore, skin adverse events have a significant impact on the quality of life of patients under treatment with targeted drugs.

Potential topics include but are not limited to the following:

  • Authors are invited to submit research papers, reviews, and clinical studies to this special issue.
  • Cutaneous toxicity associated with epidermal growth factor receptor inhibitors (anti-EGFR)
  • Cutaneous toxicity associated with small molecule tyrosine kinase inhibitors
  • Cutaneous toxicity associated with BRAF inhibitors
  • Molecular mechanisms of cutaneous toxicity induced by targeted anticancer therapy
  • Clinical cases of skin toxicity related to targeted therapy

Authors can submit their manuscripts through the Manuscript Tracking System at

Submission DeadlineFriday, 12 October 2018
Publication DateMarch 2019

Papers are published upon acceptance, regardless of the Special Issue publication date.

Special Issue Editor in Chief

Guest Editors